You're contacting media contact of this press release

Title: Telos PGX Revolutionizes Medication Management with Pharmacogenetic Testing for Medicare Beneficiaries in Long-Term Care

Telos PGX Enhances Patient Outcomes in Long-Term Care Facilities with Advanced Genetic TestingTelos PGX, an innovative pharmacogenetic laboratory based in Addison, Texas, is at the forefront of improving medication management for Medicare beneficiaries in Long-Term Care Facilities (LTCs). As the demand for personalized medicine continues to grow, Telos PGX’s cutting-edge genetic testing empowers healthcare providers to tailor drug therapies for patients in these facilities, many of whom face complex medication regimens and a heightened risk of adverse drug reactions.Long-Term Care Facilities often serve elderly populations with chronic conditions requiring multiple medications, increasing the likelihood of drug interactions and side effects. Telos PGX aims to reduce these risks by offering pharmacogenetic testing that identifies how a patient’s genetic makeup affects their response to medications. This innovative approach not only enhances patient safety but also ensures that treatments are more effective, reducing unnecessary hospitalizations and healthcare costs.With a singular focus on pharmacogenetics, Telos PGX stands out in an industry that often struggles to balance regulatory compliance, patient outcomes, and cost-efficiency. Through this specialized service, Telos PGX helps LTC facilities optimize drug therapies for some of the most vulnerable populations in healthcare.Improving Medication Safety for Medicare BeneficiariesMedicare beneficiaries in Long-Term Care Facilities represent a group with unique and often complex medical needs. Many of these individuals take multiple medications daily, and with aging bodies and altered metabolism, the risk of adverse drug reactions significantly increases. Telos PGX’s pharmacogenetic testing offers a groundbreaking solut...

This press release is issued by King Newswire